Table 1. Baseline characteristics of the patients.

	Group A	Group B
	(n = 242)	(n = 45)
Male, no. (%)	183 (75.6)	34 (75.6)
Age, years, M (range)	44 (21–81)	42 (25–67)
Weight, kg, M (range)	69 (45–139)	67 (49–116)
Risk factor for HIV, no. (%)
Previous iv drug use	80 (33.0)	14 (31.1)
Hetero/homosexual	154 (63.6)	29 (64.4)
Other	8 (3.3)	2 (4.4)
Methadone treatment, no. (%)	30 (12.3)	8 (17.7)
Nadir CD4/µl, M (range)	198 (4–762)	218 (6–480)
Clinical category C, no. (%)	57 (23.5)	9 (20.0)
Chronic hepatitis/cirrhosis, no. (%)	69 (28.5)/21 (8.6)	8 (17.7)/5 (11.1)
HCV	81 (90.0)	9 (69.2)
HBV	5 (5.5)	1 (7.6)
HCV+HVB	−	2 (14.3)
Other	3 (3.3)	2 (14.3)
No. previous ART, M (range)	2 (1–9)	2 (1–7)
Months on previous ART, M (range)	36 (1–186)	37 (3–168)
Previous antiretroviral regimen, no. (%)
EFV +2 NRTIs	134 (55.3)	38 (84.4)
NVP +2 NRTIs	16 (6.6)	7 (15.5)
IP/rtv +2 NRTIs	87 (35.9)	−
3 NRTIs	5 (2.0)	−
Previous failure on NNRTIs, no. (%)	−	45 (100)
Available genotypic resistance test, no. (%)	137 (56.6)	45 (100)
Wild type	124 (90.5)	17 (37.8)
K103N	−	22 (48.9)
L100I or K101E or V179T	−	3 (6.6)
G190A	−	2 (4.4)
CD4/µl, M (range)	473 (12–1360)	468 (31–1351)
HIV-RNA copies/ml, M (range)	<50 (<50–444867)	982 (108–170000)
HIV-RNA <50 copies/ml, no. (%)	179 (74.0)	−
Associated NRTIs, no. (%)
TDF+FTC	146 (60.3)	22 (48.9)
ABV +3TC	83 (34.3)	9 (20.0)
AZT+TDF	5 (2.1)	10 (22.2)
ABV+TDF	5 (2.1)	2 (4.4)
AZT +3TC	2 (0.8)	−
ddI +3TC	1 (0.4)	2 (4.4)
ETR 400 mg qd, no. (%)	215 (88.8)	29 (64.4)

ART: antiretroviral treatment. NRTIs: nucleos(t)ide reverse-transcriptase inhibitors. NNRTIs: non-nucleoside reverse-transcriptase inhibitors. EFV: efavirenz. NVP: nevirapine. TDF: tenofovir. FTC: emtricitabine. ABV: abacavir. 3TC: lamivudine. AZT: zidovudine.